Stock ABBV ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News AbbVie Inc.

Equities

ABBV

US00287Y1091

Real-time Estimate Cboe BZX
Other stock markets
 01:32:43 2024-04-16 pm EDT 		5-day change 1st Jan Change
162.9 USD +0.74% Intraday chart for AbbVie Inc. -4.18% +5.19%
Apr. 12 AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug MT
Apr. 12 AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant for Preventive Treatment of Migraine
AQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
BU
Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
BU
AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug
MT
AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine
CI
Ex-dividend day
FA
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
BU
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
PR
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
RE
Boehringer to lay off salespeople as Humira biosimilar sales lag
RE
Boehringer to lay off salespeople as Humira biosimilar sales lag
RE
AbbVie to Host First-Quarter 2024 Earnings Conference Call
PR
AbbVie Flags Hit to Q1 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook
MT
AbbVie : Results of Operations and Financial Condition - Form 8-K
PU
Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®
PR
US takes next step in Medicare drug price negotiations with pharma companies
RE
Roivant's anti-inflammatory drug succeeds in mid-stage study
RE
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating
MT
AbbVie - Allergan Aesthetics Launches 'Moving the Needle on Ethics' to Elevate the Conversation around Ethics in Aesthetics
AQ
Deals of the day-Mergers and acquisitions
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. News AbbVie Inc.